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Background: Pulmonary sclerosing pneumocytoma (PSP) is a rare benign pulmonary
tumor that derives from primitive respiratory epithelium of the pulmonary alveolus. The
etiology and pathogenesis are still unclear. Histopathological diagnosis focuses on cells
that are positive for TTF1, EMA, cytokeratin-7, and CAM 5.2. The aim of our study is
to highlight the elevated expression of ALDH and the presence of SOX-2 in pulmonary
sclerosing pneumocytoma.
Methods: We report five cases of pulmonary sclerosing pneumocytoma undergone
surgery at our Division of Thoracic Surgery, during a period between 1994 and 2011.
ALDH and SOX-2 markers were also tested for positivity in all the patients.
Results: Patients showed elevated expression of ALDH during immunohistochemistry
and mild expression of SOX-2, although in two cases in which SOX-2 was highly
expressed. Among these two patients, one presented with lymph node recurrence while
the other had no recurrence with a PET-positive nodule. In particular, the patient who
had developed recurrence had an ALDH score of 4 and a SOX-2 score of 3, whereas
the patient with the PET-positive nodule showed an ALDH score of 4 with a mild SOX-2
expression of score 1.
Conclusions: This is the first attempt demonstrating the elevated expression of ALDH in
this disease. SOX-2 expression was noted in both the patient who developed recurrence
and the patient with a PET-positive nodule. We believe that further investigation may
be highly useful to better characterize these two markers as well as understand
their function.
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INTRODUCTION
Pulmonary sclerosing pneumocytoma (PSP) is a rare benign
tumor in the lung (1). This disease was firstly described by
Liebow and Hubell1 as sclerosing hemangioma of the lung
owing to prominent sclerotization and vascularization of the
tissue. Pathologically, sclerosing hemangioma (SH) is typically
composed of solid, papillary, sclerotic, or hemangiomatous
components (2). The term “sclerosing hemangioma” was recently
changed in 2015 by the WHO Classification of Lung Tumors
as “pulmonary sclerosing pneumocytoma” (3). PSP was thought
to be a vascular tumor but greater knowledge of this disease
has led scientists to reconsider PSP as derived from primitive
respiratory epithelium of the pulmonary alveolus, principally
in type II alveolar cells (4). However, vascularization of this
tumor is one of the main characteristics (4). PSP is difficult
to recognize due to the lack of significant clinical or imaging
features and at first glance appears to be a benign nodule such as
hamartoma, tuberculoma, bronchial cysts, or certain lung cancer
nodules (5). Although the etiology and pathogenesis of PSP are
still unclear, recently it has been clarified that PSP is derived
from the epithelial part of the lung, which gives rise to the name
sclerosing pneumocytoma of the lung (6). PSPs are composed
of four major histologic patterns, which are hemangiomatous,
papillary, sclerotic, and solid, as well as different radiological
characteristics made apparent by computed tomography (CT)
findings according to their composition (6–14). It has been
described that PSP typically presents as a well-defined, juxta-
pleural nodule with strong and homogeneous enhancement (14–
16) on CT, while several studies have analyzed CT findings
of PSP and its pathologic correlation (14, 15). However, there
is a limitation due to the small number of patients and the
preoperative imaging modalities used in clinical practice to
diagnosis PSP (16–18). In addition, a few studies investigated PSP
using 18F-fluorodeoxyglucose positron emission tomography
(FDG PET) (19, 20). The interval between the PET and CT study
was a mean of 3.2 months (5–10); however, the hypermetabolism
in pneumocytoma has not yet been defined or correlated with the
possibility of developing into a malignant disease.
Patients are usually asymptomatic in which the PSP is
detected coincidentally. Moreover, a cough, chest pain, and
haemoptysis may also occur (6). PSP is often a solitary, well-
defined, round or oval, homogeneous nodule, or mass (14–16);
however, there are also cases of metastases to the lymph nodes,
pleura, and bones (14, 17, 18). Patients may present with a
mass lesion of up to 7 cm although 73% of lesions measure
under 3 cm (8, 10). Marginal pseudocapsules (50%), overlying
vessels (26.3%), air gap (2.6%), and halo sign (17.1%) are
among thoracic CT findings (12). Occasionally, pleural-based,
polypoid lesions may mimic a solitary fibrous tumor. Often the
tumor consists of superficial cuboidal and round interstitial cells
with a combination of four patterns. In the case of a biopsy
with a predominance of papillary components of the sclerosing
pneumocytoma, diagnosis may be difficult. In addition, both
superficial cuboidal cells and round interstitial cells are positively
immunoreactive for TTF1 and EMA (10, 19). TTF1 is used in
the diagnosis of lung adenocarcinoma and may be misleading for
diagnosing PSP. Napsin A, a human aspartic proteinase, shows
immunohistochemical reactivity in type II pneumocytes with a
granular and cytoplasmic staining pattern (18). It has been widely
used in the panel for diagnosis of lung adenocarcinoma along
with TTF-1 (17). Recently it has been demonstrated that Napsin
A preferentially stains cuboidal surface cells, rather than stromal
round cells, in sclerosing pneumocytoma (20, 21). Round cells
are generally uniformly negative for pan-cytokeratin and positive
for cytokeratin-7 and CAM 5.2 in few cases (10). However,
markers related to possible malignancy transformation have not
yet been identified.
The idea to test ALDH and SOX2 markers derives from the
consideration of the pathological characteristics of this tumor
constituted by an abundant vascularized component, and for
the roles that ALDH and SOX2 may have in the process of
endothelial vascular tumor progression. In particular, it has been
shown that ALDH is able to detect endothelial stem-like cells in
tumor with a role into the angiogenetic process (22), although
SOX2 is involved into the endothelial differentiation process
since this transcription factor have been shown to be essential
mediators in vascular development (23, 24).
For these considerations, the aim of our study is to highlight
the elevated expression of ALDH in the pneumocytoma of the
lung as described, as well as the presence of SOX-2 markers in
patients with a lymph node recurrence, and in one with a PET-
positive nodule. However, we are conscious of the limitation of
our study for the low number of patients. If the presence of these
two markers will be confirmed in a larger cohort, it would be
helpful for the setting of future target therapies, which may avoid
the patient from lung resection for a benign disease.
MATERIALS AND METHODS
We describe five patients (all female with a mean age of 54 years)
who underwent surgery in our department between 1994 and
2011 for a pulmonary sclerosing pneumocytoma of the lung. All
patients were subjected to major lung resection. The diagnosis
of pneumocytoma has been carried out by morphological
evaluation and immunostaining of transcription termination
factor 1 (TTF-1), pan-citocheratine (MNF116), and epithelial
membrane antigen (EMA) (3). No postoperative complications
were noted. Patients have been checked by the oncologist for
the definition of signs or symptoms for the disease and for the
follow-up. Data analysis was carried out by reporting descriptive
statistics of the study sample.
Immunohistochemistry and Microscopic
Evaluation
Immunohistochemical stains were performed on formalin-
fixed, paraffin-embedded 5µm sections. The sections were first
deparaffinized in xylene and further heated for 15min in a
95◦C water bath with a 10mM sodium citrate buffer, then
washed in PBS until the buffer had cooled. Incubation in
3% H2O2 at room temperature for 10min was performed.
Slides were then blocked with 10% goat serum in TBS for
15min in order to reduce non-specific background. Sectional
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incubation with rabbit monoclonal mouse anti-ALDH (1:100)
(ab−134188; Abcam, Cambridge, MA, USA) and mouse
monoclonal anti-SOX-2 (1:200) (MA1-014 Thermo Fisher
Scientific, Meridian Road Rockford, IL, USA) was performed
overnight at 4◦C. Specimens were washed in PBS and incubated
with a biotinylated secondary antibody (PK-4001; Vector Labs,
USA) for 30min at room temperature and then stained with
3,3’-Diaminobenzidine tetrahydrochloride (DAB) after which
tissue sections were counterstained with Mayer’s Hematoxylin.
A secondary antibody-only staining sample was used as a
background control to evaluate positivity for ALDH and SOX-2,
respectively. Images were collected and positivity was evaluated
by a Zeiss AxioCam ICc 3 High-Resolution through an Axioskop
microscope camera. For the assessment, section samples were
investigated employing a semi-quantitative method using a score
value for the positivity of the markers. Shown here are the
score classes: 0 (<5% positive), 1 (5–25% positive), 2 (>25–
50% positive), 3 (>50–75% positive), and 4 (>75% positive)
(25). Sections were scored by two trained investigators who were
blinded to the outcome of the patient and other clinical findings.
RESULTS
Clinical Results
All patients were free from the disease after surgery and received
a follow-up by chest and abdomen CT after 3, 6, 12, 18, 24, 36,
48, and 52 months. No recurrence was noted in four patients,
although one patient had local lymph node recurrence at station
9, 11, and 12 and therefore underwent chemotherapy. PET-CT
FDG was positive in only one patient (SUV max 2.3) for the
lung nodule.
Identification of Tumor Endothelial Cells
With High Aldehyde Dehydrogenase
Activity
To evaluate ALDH and SOX-2 positivity in these five cases
of pneumocytoma, immunohistochemistry was performed and
a score value was then assigned, as previously described (25).
Tissue sections were examined at 10, 20, and 40x magnification
to assign the appropriate values. ALDH-positive cells from tissue
slides, represented by brown cytoplasm, and SOX-2 positive
cells by brown nuclei, were both analyzed at 10, 20, and
40x magnification (Figures 1, 2). Three of the five cases of
pneumocytoma showed an ALDH score value of 4, while the
other two cases had a score value of 3. On the other hand, for
three of the five cases of pneumocytoma, SOX-2 score value was
0, despite one case having a score value of 3 while the last case
had a score value of 1.
To analyze whether ALDH is expressed in human
pneumocytoma, an immunohystochemical staining was
performed on the paraffin-embedded sections of the tumor
patient. Tissue sections were examined at 10, 20, and 40x
magnification to assign the appropriate values. ALDH staining
was strongly positive in three of the five patient cases, which had
FIGURE 1 | Immunohistochemical analysis of ALDH positive cells in five cases of pneumocytoma of the lung. Tissue sections were stained with anti-ALDH antibody
to detect the positivity in these five different cases of pneumocytoma of the lung. (A–O) Case 1, (B–P) Case 2, (C–Q) Case 3, (D–R) Case 4, (E–S) Case 5.
Semi-quantitative method was used to assess the ALDH positivity of the tumor cells: 0 (<5% positive), 1 (5–25% positive), 2 (>25–50% positive), 3 (>50–75%
positive), and 4 (>75% positive). Representative images of the five cases, stained for ALDH, are shown at 10, 20, and 40x magnification. Representative images
corresponding to each tumor samples stained with hematoxylin and eosin (U, V, X, W, Z) are shown at 10x magnification. Isotype control for ALDH antibody was
shown (F, N, T). Scale bar = 100µm.
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FIGURE 2 | Immunohistochemical analysis of SOX-2 positive cells in five cases of pneumocytoma of the lung. Tissue sections were stained with anti-SOX-2 antibody
to detect the positivity in these five different cases of pneumocytoma of the lung. (A–O) Case 1, (B–P) Case 2, (C–Q) Case 3, (D–R) Case 4, (E–S) Case 5.
Semi-quantitative method was used to assess the SOX-2 positivity of the tumor cells: 0 (<5% positive), 1 (5–25% positive), 2 (>25–50% positive), 3 (>50–75%
positive), and 4 (>75% positive). Representative images of the five cases are shown at 10, 20, and 40x magnification. Isotype control for SOX-2 antibody was shown
(F, N, T). Scale bar = 100µm.
TABLE 1 | Patients characteristics.
Patient Tumor hystotype
and
characteristic
ALDH
expression
SOX-2
expression
Pt#1 Pneumocytoma 3 0
Pt#2 Pneumocytoma 4 1
Pt#3 Pneumocytoma 4 3
Pt#4 Pneumocytoma 4 0
Pt#5 Pneumocytoma
with lymphonodes
local recurrence
3 0
This table represents the five patients case of pneumocytoma analyzed for the
immunohystochemical expression of ALDH and SOX-2. A score value for ALDH and SOX-
2 was assigned using the following score classes: 0 (<5% positive), 1 (5–25% positive),
2 (>25–50% positive), 3 (>50–75% positive), and 4 (>75% positive).
a score value of 4 (Figures 1B–R, Table 1). Regarding the other
two patients, ALDH was strongly positive, with a score value of 3
(Figures 1A–O,S, Table 1).
Identification of Cells Expressing Stem Cell
Factor SOX-2
To evaluate SOX-2 positivity in these five cases of
pneumocytoma, immunohistochemistry was performed,
and a score value was assigned as previously described (25).
Tissue sections were examined at 10, 20, and 40x magnification
to assign the appropriate values. SOX-2 positive cells were
represented by brown nuclei and were analyzed at 10, 20,
and 40x magnification (Figure 2). Three of the five patient
cases of pneumocytoma had a SOX-2 score value equal to
0 (Figures 2A-S, Table 1), while the remaining two patients
had a score value of 3 (Figures 2C–Q) and a score value of 1
(Figures 2B–P, Table 1).
DISCUSSION
Pulmonary sclerosing pneumocytoma (PSP) is a rare benign
tumor typically occurring in women with a favorable prognosis.
Recurrence for this disease is infrequent, although not
impossible to find. The nomenclature for this benign disease
(8–10) has recently been renamed “pulmonary sclerosing
pneumocytoma” (6).
It is extremely difficult to obtain an accurate diagnosis
for PSP due to its low incidence and the impossibility of
establishing a clinical and radiological differential diagnosis
from other diseases. This is well-documented in the scientific
literature where surgery is the gold standard treatment and
the most common immunohistochemistry markers are used
for diagnosis (Table 2) (15). Moreover, due to the frequent
expression in females, estrogen receptors have been studied using
immunohistochemistry, which has revealed an overexpression of
ERbeta in 91.9% of patients affected by the disease (19, 20). The
frequent markers used for diagnosis indicate positivity for EMA
(epithelial membrane antigen), TTF-1 (transcription termination
factor 1), and CK-7 (cytokeratin-7) staining (Table 2) (18, 26–
35). However, currently no specific markers in this type of benign
tumor have been identified.
Our study is the first attempt to show the presence of ALDH
and SOX-2 in pulmonary sclerosing pneumocytoma of the lung.
In particular, we decided to test ALDH and SOX2 in our PSP
samples for the well-known vascular aspect of this tumor which
may be associated with the role that these two markers have
into the tumor vascularization process. Recently, it has been
revealed that tumor endothelial cells were different from normal
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TABLE 2 | Review of the literature regarding PSP of the lung.
Author/year Patients
enrolled (n)
Gender
(M/F)
Age
(Mean)
Type of treatment IHC marker Methastatic
lymphonodes
Recurrence
Hu et al. (26) 46 5M
41F
51.4 45/46 Surgery
−21 enucleation
−9 wedge resections
−15 lobectomies
/ / No
Devouassoux-
Shisheboran et al. (18)
100 17M
83F
46 54/100 Surgery:
5 wedge resections
37 lobectomies
2 bilobectomies
1 pneumonectomy
- 9 procedures not specified
specificata
-pancytokeratin+; CAM
5.2+, CK7 +, EMA +
calretinin –; CK5/6 –
TTF1 +; Sp A e B +
chromogranin –;
synaptophysin –; Leu 7 –
- S100 -
Yes, 1 case No
Shin et al. (27) 76 9M
67F
50 45/76 Surgery:
33 segmentectomies
11 lobectomies
- 1 bilobectomies
TTF1+, cytokeratin +,
EMA+;
- ki-67–
/ /
Yang et al. (28) 59 2M
57F
49.85 Wedge resection (58 wedge
resections)
Surface cell AE1/AE3+ e
CK7+;
Stromal cell AE1/AE3-
e CK7+;
- TTF1+ e EMA+
No No
Lei et al. (29) 28 3M
25F
46.1 13 enucleation
7 wedge resection
8 lobectomies
/ No Yes
Park et al. (30) 32 1M
31F
47.8 19 lobectomies
5 wedge resections
1 segmentectomy
7 wedge resections
/ Yes, 1 case No
Cho et al. (31) 11 1M
10F
48.6 Surgery MMP-9 +
Tubulinα +
IGF1 +
/ /
Schmidt (32) 6 / / / TTF1 +
Napsin A +
/ /
Wu et al. (33) 18 2M
16F
44.6 / P40 +
TTF1+, SHL+,
EMA+, Vimentin+
No No
Lovrenski et al. (34) 6 1M
5F
/ Surgery TTF1+ e panCK + No No
This Table shows treatments and immunohistochemical characteristics. ALDH and SOX-2 have been never considered.
endothelial cells in various aspects such as gene expression
profiles and for the activities of the ALDH, enzyme that plays a
key role in the metabolism of aldehydes. Several studies showed
that different type of stem cell types including hematopoietic
stem cells and neural stem cells possess high ALDH activities.
Thus, ALDH is used extensively as a stem cell marker, also for
endothelial stem-like cells (22). Scientific advantages have shown
that ALDH is upregulated in human endothelial cells in vivo and
may be involved in tumor angiogenesis in cancer patients (36).
There is likely an important role for ALDH in the formation of
this tumor, which derives from vascular endothelial cells. On this
marked trail, our results show a very high expression of ALDH
(score of 4) in three patients and a high expression (score of
3) in the other two patients. Additionally, we found that the
positivity of ALDH was sparsely distributed within the tumor,
which may support endothelial cell heterogeneity. This concept
may be attributed to the fact that ALDH expression levels are
linked to the tumor microenvironment or tumor malignancy,
which may affect ALDH expression in the endothelial cells
themselves (37). Furthermore, the evaluation of SOX-2 in our
patients’ tumors derived from the knowledge that SOX-2 is
known to play an important role in vascular development
and disease, since its transcription factors have been shown
to be essential mediators in vascular development, and in the
developing endothelium (23). The involvement of SOX-2 may
be crucial also for the angiogenesis in this type of tumor,
synergistically participating with ALDH positive cells in the
vascular impairment of pneumocytoma (22). Interestingly, SOX-
2 was found to be highly expressed (score of 3) in only one
patient: the same patient showing an ALDH score of 4 and lymph
node recurrence, which is highly uncommon for this disease (24).
Although we are conscious of the fact that our study focuses
on a small number of patients, due to the rarity of this benign
disease of the lung, we strongly believe that the presence of
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ALDH and SOX-2 in pneumocytoma of the lung requires deeper
analysis, especially in patients who show recurrence. This will
be helpful for understanding the molecular mechanisms behind
the phenomenon, and for developing future targeted therapies,
which may be more effective than surgery in removing or
controlling the disease.
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